Download PDF
Semin Reprod Med 2000; 18(4): 369-378
DOI: 10.1055/s-2000-13727
Copyright © 2000 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Thrombophilia and Adverse Pregnancy Outcome

Raj Rai, Lesley Regan
  • Department of Reproductive Science and Medicine, Imperial College School of Medicine at St. Mary's, London, United Kingdom
Further Information

Publication History

Publication Date:
31 December 2000 (online)

    Permissions and Reprints

ABSTRACT

The hemostatic system plays an important role in three crucial stages of pregnancy: ovulation, implantation, and placentation. A thrombophilic defect is an abnormality in the coagulation pathways that predisposes an individual to thrombosis. Pregnancy is a hypercoaguable state and interest has focused on the potential role that thrombophilic defects may play in the etiology not only of recurrent miscarriage but also of late pregnancy complications. Maternal intervillous blood flow does not develop to any significant extent before 8 weeks of gestation and thrombophilic defects are therefore unlikely to contribute to pregnancy loss before this time. Retrospective studies have reported a similar prevalence of genetic thrombophilic defects among women with recurrent first-trimester miscarriage and controls but an increased prevalence among those with second-trimester miscarriage and later pregnancy complications. There is a paucity of data documenting the prospective outcome of untreated pregnancies among women with thrombophilic defects and of the placental histology in these pregnancies. Until these issues have been addressed, routine thromboprophylaxis during pregnancy cannot be recommended for women with thrombophilic abnormalities.

KEYWORD

Thrombophilia - pregnancy - recurrent miscarriage

REFERENCES

  • 1 Kutteh W H. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone.  Am J Obstet Gynecol . 1996;  174 1584-1589
    CrossrefPubMedGoogle Scholar
  • 2 Rai R, Cohen H, David M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies).  Br Med J . 1997;  314 253-257
    CrossrefPubMedGoogle Scholar
  • 3 Stirling Y, Woolf L, North W R, Seghatchian M J, Meade T W. Haemostasis in normal pregnancy.  Thromb Haemost . 1984;  52 176-182
    PubMedGoogle Scholar
  • 4 Bonnar J. Haemostasis and coagulation disorders in pregnancy. In: Bloom A, Thomas DP, eds. Haemostasis and Thrombosis Edinburgh: Churchill Livingstone 1981: 454
    Google Scholar
  • 5 Cumming A M, Tait R C, Fildes S, Yoong A, Keeney S, Hay C RM. Development of resistance to activated protein C during pregnancy.  Br J Haematol . 1995;  90 725-727
    CrossrefPubMedGoogle Scholar
  • 6 Comp P C, Thurnau G R, Welsh J, Esmon C T. Functional and immunologic protein S levels are decreased during pregnancy.  Blood . 1986;  68 881-885
    PubMedGoogle Scholar
  • 7 de Boer K, ten Cate W J, Sturk A, Borm J J, Treffers P E. Enhanced thrombin generation in normal and hypertensive pregnancy.  Am J Obstet Gynecol . 1989;  160 95-100
    PubMedGoogle Scholar
  • 8 Lao T T, Yuen P M, Yin J A. Protein S and protein C levels in Chinese women during pregnancy, delivery and the puerperium.  Br J Obstet Gynaecol . 1989;  96 167-170
    PubMedGoogle Scholar
  • 9 Faught W, Garner P, Jones G, Ivey B. Changes in protein C and protein S levels in normal pregnancy.  Am J Obstet Gynecol . 1995;  172 147-150
    CrossrefPubMedGoogle Scholar
  • 10 Weenink G H, Treffers P E, Kahle L H, ten Cate W J. Antithrombin III in normal pregnancy.  Thromb Res . 1982;  26 281-287
    CrossrefPubMedGoogle Scholar
  • 11 Bremme K, Ostlund E, Almqvist I, Heinonen K, Blomback M. Enhanced thrombin generation and fibrinolytic activity in normal pregnancy and the puerperium.  Obstet Gynecol . 1992;  80 132-137
    PubMedGoogle Scholar
  • 12 Cadroy Y, Grandjean H, Pichon J. Evaluation of six markers of haemostatic system in normal pregnancy and pregnancy complicated by hypertension or pre-eclampsia.  Br J Obstet Gynaecol . 1993;  100 416-420
    PubMedGoogle Scholar
  • 13 Halligan A, Bonnar J, Sheppard B, Darling M, Walshe J. Haemostatic, fibrinolytic and endothelial variables in normal pregnancies and pre-eclampsia.  Br J Obstet Gynaecol . 1994;  101 488-492
    PubMedGoogle Scholar
  • 14 Stegnar M, Zore A, Novak-Antolic Z, Vovk N, Kruithof E K. Tissue-type plasminogen activator after venous occlusion in pregnancy and puerperium.  Thromb Haemost . 1993;  70 486-490
    PubMedGoogle Scholar
  • 15 Burgess-Wilson M E, Morrison R, Heptinstall S. Spontaneous platelet aggregation in heparinised blood during pregnancy.  Thromb Res . 1986;  41 385-393
    CrossrefPubMedGoogle Scholar
  • 16 Louden K A, Broughton P F, Heptinstall S, Fox S C, Mitchell J R, Symonds E M. Platelet reactivity and serum thromboxane B2 production in whole blood in gestational hypertension and pre-eclampsia.  Br J Obstet Gynaecol . 1991;  98 1239-1244
    CrossrefPubMedGoogle Scholar
  • 17 Fitzgerald D J, Mayo G, Catella F, Entman S S, FitzGerald G A. Increased thromboxane biosynthesis in normal pregnancy is mainly derived from platelets.  Am J Obstet Gynecol . 1987;  157 325-330
    PubMedGoogle Scholar
  • 18 Horn E H, Cooper J, Hardy E, Heptinstall S, Rubin P C. A cross-sectional study of platelet cyclic AMP in healthy and hypertensive pregnant women.  Clin Sci . 1991;  80 549-558
    PubMedGoogle Scholar
  • 19 Rushton D I. Placental pathology in spontaneous miscarriage. In: Beard RW, Sharp F, eds. Early Pregnancy Loss: Mechanisms and Treatment London: RCOG 1988: 149-158
    Google Scholar
  • 20 Out H J, Kooijman C D, Bruinse H W, Derksen R H. Histopathological findings in placentae from patients with intra-uterine fetal death and anti-phospholipid antibodies.  Eur J Obstet Gynecol Reprod Biol . 1991;  41 179-186
    CrossrefPubMedGoogle Scholar
  • 21 Dizon T D, Meline L, Nelson L M, Varner M, Ward K. Fetal carriers of the factor V Leiden mutation are prone to miscarriage and placental infarction.  Am J Obstet Gynecol . 1997;  177 401-405
    PubMedGoogle Scholar
  • 22 Preston F E, Rosendaal F R, Walker I D, Briet E, Berntorp E. Increased fetal loss in women with heritable thrombophilia.  Lancet . 1996;  348 913-916
    CrossrefPubMedGoogle Scholar
  • 23 Ramsey E M, Donner N W. Placental vasculature and circulation.  Stuttgart: George Thieme; 1980
    Google Scholar
  • 24 Jauniaux E, Jurkovic D, Campbell S, Hustin J. Doppler ultrasonographic features of the developing placental circulation: correlation with anatomic findings.  Am J Obstet Gynecol . 1992;  166 585-587
    PubMedGoogle Scholar
  • 25 Jaffe R, Woods J RJ. Color Doppler imaging and in vivo assessment of the anatomy and physiology of the early uteroplacental circulation.  Fertil Steril . 1993;  60 293-297
    PubMedGoogle Scholar
  • 26 Coppens M, Loquet P, Kollen M, De Neubourg F, Buytaert P. Longitudinal evaluation of uteroplacental and umbilical blood flow changes in normal early pregnancy.  Ultrasound Obstet Gynecol . 1996;  7 114-121
    CrossrefPubMedGoogle Scholar
  • 27 Burton G J, Jauniau E, Watson A L. Maternal arterial connections to the placental intervillous space during the first trimester of human pregnancy: the Boyd collection revisited. Am J Obstet Gynecol .  1999;  181 718-724
    CrossrefPubMedGoogle Scholar
  • 28 Rai R, Regan L, Hadley E, Dave M, Cohen H. Second-trimester pregnancy loss is assocaited with activated protein C resistance.  Br J Haematol . 1996;  92 489-490
    PubMedGoogle Scholar
  • 29 Vincent T, Rai R, Regan L, Cohen H. Increased thrombin generation in women with recurrent miscarriage [letter].  Lancet . 1998;  352 116
    CrossrefPubMedGoogle Scholar
  • 30 Gris J C, Ripart N S, Maugard C. Respective evaluation of the prevalence of haemostasis abnormalities in unexplained primary early recurrent miscarriages: the Nimes Obstetricians and Haematologists (NOHA) Study.  Thromb Haemost . 1997;  77 1096-1103
    PubMedGoogle Scholar
  • 31 Laskin C A, Chuma A, Angelov L. Sera from habitual aborters induce monocyte procoagulant activity: a lymphocyte-dependent event.  Clin Immunol Immunopathol . 1994;  73 235-244
    CrossrefPubMedGoogle Scholar
  • 32 Tulppala M, Marttunen M, Soderstrom-Anttila V. Low-dose aspirin in prevention of miscarriage in women with unexplained or autoimmune related recurrent miscarriage: effect on prostacyclin and thromboxane A2 production.  Hum Reprod . 1997;  12 1567-1572
    CrossrefPubMedGoogle Scholar
  • 33 Woodhams B J, Candotti G, Shaw R, Kernoff P BA. Changes in coagulation and fibrinolysis during pregnancy: evidence of activation of coagulation preceding spontaneous abortion.  Thromb Res . 1989;  55 99-107
    CrossrefPubMedGoogle Scholar
  • 34 Rosendaal F R, Koster T, Vandenbroucke J P, Reitsma P H. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance).  Blood . 1995;  85 1504-1508
    PubMedGoogle Scholar
  • 35 Hellgren M, Svensson P J, Dahlbaeck B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives.  Am J Obstet Gynecol . 1995;  173 210-213
    CrossrefPubMedGoogle Scholar
  • 36 Rai R S, Regan L, Chitolie A, Donald J G, Cohen H. Plascental thrombosis and second trimester miscarriage in association with activated protein C resistance.  Br J Obstet Gynaecol . 1996;  103 842-844
    PubMedGoogle Scholar
  • 37 Gopel W, Kim D, Gortner L. Prothrombotic mutations as a risk factor for preterm birth [letter].  Lanced . 1999;  353 1411-1412
    PubMedGoogle Scholar
  • 38 Poort S R, Rosendaal F R, Reitsma P H, Bertina R M. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis.  Blood . 1996;  88 3698-3703
    CrossrefPubMedGoogle Scholar
  • 39 Franco R F, Trip M D, ten Cate H. The 20210 G→A mutation in the 3'-untranslated region of the prothrombin gene and the risk for arterial thrombotic disease.  Br J Haematol . 1999;  104 50-54
    CrossrefPubMedGoogle Scholar
  • 40 Sun W Y, Witte D P, Degen J L. Prothrombin deficiency results in embryonic and neonatal lethality in mice.  Proc Natl Acad Sci U S A . 1998;  95 7597-7602
    CrossrefPubMedGoogle Scholar
  • 41 Frosst P, Blom H J, Milos R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase [letter].  Nat Genet . 1995;  10 111-113
    CrossrefPubMedGoogle Scholar
  • 42 Kluijtmans L A, van den Heuvel P L, Boers G H. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease.  Am J Hum Genet . 1996;  58 35-41
    PubMedGoogle Scholar
  • 43 Rai R, Regan L, Hadley E, Dave M, Cohen H. Second-trimester pregnancy loss is associated with activated C resistance.  Br J Haematol . 1996;  92 489-490
    PubMedGoogle Scholar
  • 44 Coumans A B, Juijgens P C, Jakobs C. Haemostatic and metabolic abnormalities in women with unexplained recurrent abortion.  Hum Reprod . 1999;  14 211-214
    CrossrefPubMedGoogle Scholar
  • 45 Tal J, Schliamser L M, Leibovitz Z, Ohel G, Attias D. A possible role for activated protein C resistance in patients with first and second trimester pregnancy failure.  Hum Reprod . 1999;  14 1624-1627
    CrossrefPubMedGoogle Scholar
  • 46 Strickland S, Reich E, Sherman M I. Plasminogen activator in early embryogenesis: enzyme production by trophoblast and parietal endoderm.  Cell . 1976;  9 231
    CrossrefPubMedGoogle Scholar
  • 47 Sappino A P, Huarte J, Belin D. Plasminogen activators in tissue remodelling and invasion: mRNA localization in mouse ovaries and implanting embryos.  J Cell Biol . 1989;  109 2471
    CrossrefPubMedGoogle Scholar
  • 48 Hoffman G E, Glatstein I, Schatz F. Immunohistochemical localization of urokinase type plasminogen activator and plasminogen activator inhibitors 1 and 2 in early human implantation sites.  Am J Obstet Gynecol . 1994;  170 671
    PubMedGoogle Scholar
  • 49 van Pampus G M, Dekker G A, Wolf H. High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia.  Am J Obstet Gynecol . 1999;  180 1146-1150
    CrossrefPubMedGoogle Scholar
  • 50 Lindoff C, Ingemarsson I, Martinsson G, Segelmark M, Thysell H, Astedt B. Preeclampsia is associated with a reduced response to activated protein C.  Am J Obstet Gynecol . 1997;  176 457-460
    PubMedGoogle Scholar
  • 51 Kupferminc M J, Eldor A, Steinman N. Increased frequency of genetic thrombophilia in women with complications of pregnancy.  N Engl J Med . 1999;  340 9-13
    CrossrefPubMedGoogle Scholar
  • 52 Sanson B-J, Freiderich P W, Simioni P. The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women.  Thromb Haemost . 1996;  75 387-388
    PubMedGoogle Scholar
  • 53 Sibai B M. Thrombophilias and adverse outcomes of pregnancy: what should a clinician do?.  N Engl J Med . 1999;  340 50-52
    CrossrefPubMedGoogle Scholar
  • 54 De Stefano V, Martinelli I, Mannucci P M. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation.  N Engl J Med . 1999;  341 801-806
    CrossrefPubMedGoogle Scholar
  • 55 Balasch J, Reverter J C, Fabregues F. First-trimester repeated abortion is not associated with activated protein C resistance.  Hum Reprod . 1997;  12 1094-1097
    CrossrefPubMedGoogle Scholar
  • 56 Brenner B, Mandel H, Lanir N. Activated protein C resistance can be associated with recurrent fetal loss.  Br J Haematol . 1997;  97 551-554
    CrossrefPubMedGoogle Scholar
  • 57 Grandone E, Margaglione M, Colaizzo D. Factor V Leiden is associated withr epeated and recurrent unexplained fetal losses.  Thromb Haemost . 1997;  77 822-824
    PubMedGoogle Scholar
  • 58 Dizon-Townson D S, Kinney S, Branch D W, Ward K. The factor V Leiden mutation is not a common cause of recurrent miscarriage.  J Reprod Immunol . 1997;  34 217-223
    PubMedGoogle Scholar
  • 59 Metz J, Kloss M, O'Malley C J. Prevalence of factor V Leiden is not increased in women with recurrent miscarriage.  Clin Appl Thromb Hemost . 1997;  3 137-140
    PubMedGoogle Scholar
  • 60 Ridker P M, Miletich J P, Buring J E. Factor V Leiden mutation as a risk factor for recurrent pregnancy loss.  Ann Intern Med . 1998;  128 1000-1003
    PubMedGoogle Scholar
  • 61 Kutteh W H, Park V M, Deitcher S R. Hypercoagulable state mutation analysis in white patients with early first-trimester recurrent pregnancy loss.  Fertil Steril . 1998;  71 1048-1053
    PubMedGoogle Scholar
  • 62 Brenner B, Sarig G, Weiner Z, Younis J, Blumenfeld Z, Lanir N. Thrombophilic polymorphisms are common in women with fetal loss without apparent cause.  Thromb Haemost . 1999;  82 6-9
    PubMedGoogle Scholar
  • 63 Souza S S, Ferriani R A, Pontes A G, Zago M A, Franco R F. Factor V Leiden and factor II G20210A mutations in patients with recurrent abortion.  Hum Reprod . 1999;  14 2448-2450
    CrossrefPubMedGoogle Scholar
  • 64 Holmes Z R, Regan L, Chilcott I, Cohen H. The C677T MTHFR gene mutation is not predictive of risk for recurrent fetal loss.  Br J Haematol . 1999;  105 98-101
    CrossrefPubMedGoogle Scholar